ethyl 2-(bromomethyl)-1-(phenylsulfonyl)-1H-pyrrole-3-carboxylate | 934621-65-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 2-(bromomethyl)-1-(phenylsulfonyl)-1H-pyrrole-3-carboxylate
• 英文别名: ethyl 1-(benzenesulfonyl)-2-(bromomethyl)pyrrole-3-carboxylate
• CAS: 934621-65-5
• 化学式: C₁₄H₁₄BrNO₄S
• 分子量: 372.239
• InChiKey: LSCCPOGHMQRWBI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  73.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 2-(bromomethyl)-1-(phenylsulfonyl)-1H-pyrrole-3-carboxylate 在 sodium hydride 、 三乙胺 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 methyl 1-(phenylsulfonyl)-4-{[(trifluoromethyl)sulfonyl]oxy}-1H-pyrrolo[2,3-c]pyridine-5-carboxylate
  参考文献：
  名称：

  Design and Synthesis of Novel N-Hydroxy-Dihydronaphthyridinones as Potent and Orally Bioavailable HIV-1 Integrase Inhibitors

  摘要：

  HIV-1 integrase (IN) is one of three enzymes encoded by the HIV genome and is essential for viral replication, and HIV-1 IN inhibitors have emerged as a new promising class of therapeutics. Recently, we reported the synthesis of orally bioavailable azaindole hydroxamic acids that were potent inhibitors of the HIV-1 IN enzyme. Here we disclose the design and synthesis of novel tricyclic N-hydroxy-dihydronaphthyridinones as potent, orally bioavailable HIV-1 integrase inhibitors displaying excellent ligand and lipophilic efficiencies.

  DOI：

  10.1021/jm200208d
• 作为产物：
  描述：

  2-甲基吡咯-3-甲酸乙酯 在 N-溴代丁二酰亚胺(NBS) 、 四丁基溴化铵 、 sodium hydroxide 、 过氧化苯甲酰 作用下， 以 四氯化碳 、 水 、 甲苯 为溶剂， 反应 2.75h， 生成 ethyl 2-(bromomethyl)-1-(phenylsulfonyl)-1H-pyrrole-3-carboxylate
  参考文献：
  名称：

  Design and Synthesis of Novel N-Hydroxy-Dihydronaphthyridinones as Potent and Orally Bioavailable HIV-1 Integrase Inhibitors

  摘要：

  HIV-1 integrase (IN) is one of three enzymes encoded by the HIV genome and is essential for viral replication, and HIV-1 IN inhibitors have emerged as a new promising class of therapeutics. Recently, we reported the synthesis of orally bioavailable azaindole hydroxamic acids that were potent inhibitors of the HIV-1 IN enzyme. Here we disclose the design and synthesis of novel tricyclic N-hydroxy-dihydronaphthyridinones as potent, orally bioavailable HIV-1 integrase inhibitors displaying excellent ligand and lipophilic efficiencies.

  DOI：

  10.1021/jm200208d

文献信息

• INHIBITORS OF THE HIV INTEGRASE ENZYME
  申请人：Dress Ruprecht Klaus

  公开号：US20070099915A1

  公开（公告）日：2007-05-03

  The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIV”) integrase enzyme.

  本发明涉及式（I）的化合物，以及其在药学上可接受的盐和溶剂化合物，它们的合成，以及它们作为人类免疫缺陷病毒（“HIV”）整合酶的调节剂或抑制剂的用途。
• [EN] INHIBITORS OF THE HIV INTEGRASE ENZYME<br/>[FR] INHIBITEURS DE L'ENZYME INTÉGRASE DU VIH
  申请人：PFIZER PROD INC

  公开号：WO2007042883A1

  公开（公告）日：2007-04-19

  [EN] The present invention is directed to compounds of Formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus ("HIV") integrase enzyme.
  [FR] La présente invention concerne des composés de formule (I) et leurs sels et solvates pharmaceutiquement acceptables, leur synthèse et leur utilisation en tant que modulateurs ou inhibiteurs de l'enzyme intégrase du virus de l'immunodéficience humaine ('VIH').